BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6771598)

  • 1. [Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].
    Balda BR; Bassermann R
    MMW Munch Med Wochenschr; 1980 May; 122(21):792-4. PubMed ID: 6771598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
    Leyh F; Winzer M; Weber M; Hypa F
    Z Hautkr; 1985 Jun; 60(12):961-72. PubMed ID: 4024678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
    Doering C; Pickartz H; Orfanos CE; Altenähr E
    Z Hautkr; 1982 Jul; 57(13):971-80. PubMed ID: 7113323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
    Runne U; Doepfmer K; Antz H; Groth W; FEAUX DE Lacroix W
    Dtsch Med Wochenschr; 1980 Feb; 105(7):230-3. PubMed ID: 6986251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Budd-Chiari syndrome in DTIC therapy].
    Swensson-Beck H; Trettel WH
    Hautarzt; 1982 Jan; 33(1):30-1. PubMed ID: 7085277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DTIC: effect on fibrinolysis and thrombocyte function].
    Biltz H; Budde U; Fiedler U; Harbrecht U; Kreysel HW
    Onkologie; 1986 Oct; 9(5):270-3. PubMed ID: 3543778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.
    Marsh JC
    Hepatology; 1989 May; 9(5):790-2. PubMed ID: 2707742
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
    Frosch PJ; Czarnetzki BM; Macher E; Grundmann E; Gottschalk I
    J Cancer Res Clin Oncol; 1979; 95(3):281-6. PubMed ID: 528568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
    Erichsen C; Jönsson PE
    J Surg Oncol; 1984 Dec; 27(4):268-70. PubMed ID: 6503301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
    Ceci G; Bella M; Melissari M; Gabrielli M; Bocchi P; Cocconi G
    Cancer; 1988 May; 61(10):1988-91. PubMed ID: 3359400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic veno-occlusive disease due to DTIC.
    Asbury RF; Rosenthal SN; Descalzi ME; Ratcliffe RL; Arseneau JC
    Cancer; 1980 May; 45(10):2670-4. PubMed ID: 7379000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budd-Chiari syndrome in women taking oral contraceptives.
    Tsung SH; Han D; Loh WP; Lin JI
    Ann Clin Lab Sci; 1980; 10(6):518-22. PubMed ID: 7447394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Photosensitization with DTIC therapy in metastatic malignant melanoma].
    Bolling R; Meyer-Hamme S; Schauder S
    Hautarzt; 1980 Nov; 31(11):602-5. PubMed ID: 7451142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergy-induced hepatic toxicity associated with dacarbazine.
    McClay E; Lusch CJ; Mastrangelo MJ
    Cancer Treat Rep; 1987 Feb; 71(2):219-20. PubMed ID: 3802121
    [No Abstract]   [Full Text] [Related]  

  • 15. [Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
    Voigt H; Caselitz J; Jänner M
    Klin Wochenschr; 1981 Mar; 59(5):229-36. PubMed ID: 7218735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.
    Pritchard KI; Quirt IC; Cowan DH; Osoba D; Kutas GJ
    Cancer Treat Rep; 1980; 64(10-11):1123-6. PubMed ID: 7459898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological aspects of dacarbazine-induced human liver damage.
    Paschke R; Heine M
    Hepatogastroenterology; 1985 Dec; 32(6):273-5. PubMed ID: 4093126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation.
    Attwell A; Ludkowski M; Nash R; Kugelmas M
    Aliment Pharmacol Ther; 2004 Oct; 20(8):867-73. PubMed ID: 15479358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
    Herishanu Y; Lishner M; Kitay-Cohen Y
    Anticancer Drugs; 2002 Feb; 13(2):177-9. PubMed ID: 11901312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.